{"id":"W2111658171","doi":"10.1016/j.ygyno.2015.04.009","title":"A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia","year":2015,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ovarian cancer; Fallopian tube; Internal medicine; Gastroenterology; Clinical endpoint; Fallopian tube cancer; Phases of clinical research; Progression-free survival; Chemotherapy; Gynecology; Urology; Surgery; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005299831,0.001680339,0.00212721,0.0006341264,0.000800334,0.001414363,0.000964282,0.00242607,0.005351255],"category_scores_gemma":[0.003505414,0.0007818662,0.002362661,0.0005751928,0.001019677,0.0008930601,0.0006396272,0.003614095,0.0007732096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001189605,"about_ca_system_score_gemma":0.00314791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002384599,"about_ca_topic_score_gemma":0.006599065,"domain_scores_codex":[0.998778,0.0008145598,0.0000442747,0.0001395433,0.0001023949,0.0001211852],"domain_scores_gemma":[0.9982253,0.0004564068,0.0003265864,0.0001522161,0.0001314015,0.000708244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9238213,0.01003482,0.00328588,0.0008812767,0.002137689,0.00008973061,0.0001889173,0.001059971,0.004806093,0.0005494989,0.00835659,0.04478818],"study_design_scores_gemma":[0.9694251,0.02540502,0.00216334,0.00003180445,0.0003654679,0.0000370539,0.00001699312,0.0002828179,0.000266562,0.0001014518,0.00189183,0.00001253289],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9470238,0.01548306,0.002139146,0.005536983,0.001490584,0.0146619,0.004962539,0.0002925326,0.008409519],"genre_scores_gemma":[0.9320753,0.009982685,0.009023676,0.00732486,0.001153571,0.01938765,0.007509149,0.0001167209,0.01342648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005351255,"threshold_uncertainty_score":0.02802855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09231435434348424,"score_gpt":0.3957769751900425,"score_spread":0.3034626208465582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}